

HR 6478

Biosimilars Competition Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 23, 2018

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jul 27, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/6478>

Sponsor

Name: Rep. Sarbanes, John P. [D-MD-3]

Party: Democratic • **State:** MD • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Johnson, Bill [R-OH-6]	R · OH		Jul 23, 2018

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 27, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jul 23, 2018)

Biosimilars Competition Act of 2018

This bill amends the Public Health Service Act to require a biologic manufacturer and a biosimilar drug manufacturer to provide notification to the Department of Justice and the Federal Trade Commission regarding certain pharmaceutical agreements. The agreements requiring notice are those related to the manufacturer, marketing or sale of the biosimilar product or the reference product.

Biosimilars are biological products approved by the Food and Drug Administration based on their similarity to an already-approved biological product.

Actions Timeline

- **Jul 27, 2018:** Referred to the Subcommittee on Health.
- **Jul 23, 2018:** Introduced in House
- **Jul 23, 2018:** Referred to the House Committee on Energy and Commerce.